No, Aquestive Therapeutics does not pay dividends to its common shareholders. As a clinical-stage and specialty pharmaceutical enterprise focused heavily on funding research, clinical trials, and commercialization pathways for its proprietary drug candidates, the company retains all available capital to support ongoing corporate operations and pipeline expansion rather than distributing cash returns to investors.